BioPharmSignal logoBioPharmSignal

Biotech News

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Personalis (PSNL)PersonalisConference / presentation

Podium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer; Real-world data from 10,000 patients reinforce industry-leading sensitivity; Data presented for a new NeXT Personal feature for monitoring resistance mutations FREMONT, Calif. --(BUSINESS WIRE)--Apr.

Related news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

PSNLPersonalis2026-07-14 10:00 EST

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

GSKGSK plc2026-07-29 09:08 EST

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

View all latest news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

PSNLPersonalis2026-07-20 12:30 EST

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

PSNLPersonalis2026-07-14 10:00 EST

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

PSNLPersonalis2026-06-09 10:00 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-02 10:00 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Stock data

Close
18.38 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States